REPL Key Statistics, Chart & Performance
The current stock price of REPL is 9.9654 USD. In the past month the price increased by 1.13%. In the past year, price decreased by -22.19%.
REPL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.28B | ||
| AMGN | AMGEN INC | 15.03 | 177.01B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.25 | 115.63B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 787.76 | 53.08B | ||
| INSM | INSMED INC | N/A | 37.20B | ||
| NTRA | NATERA INC | N/A | 31.79B | ||
| BIIB | BIOGEN INC | 10.57 | 25.95B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.69 | 21.24B | ||
| INCY | INCYTE CORP | 15.45 | 19.47B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.33B |
Related stock screener links
About REPL
Company Profile
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Company Info
REPLIMUNE GROUP INC
500 Unicorn Park Dr
Woburn MASSACHUSETTS 01801 US
CEO: Philip Astley-Sparke
Employees: 479
Phone: 17812229600
REPLIMUNE GROUP INC / REPL FAQ
What does REPL do?
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Can you provide the latest stock price for REPLIMUNE GROUP INC?
The current stock price of REPL is 9.9654 USD. The price increased by 1.48% in the last trading session.
Does REPL stock pay dividends?
REPL does not pay a dividend.
What is the ChartMill technical and fundamental rating of REPL stock?
REPL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for REPL stock?
The Revenue of REPLIMUNE GROUP INC (REPL) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is REPLIMUNE GROUP INC worth?
REPLIMUNE GROUP INC (REPL) has a market capitalization of 781.69M USD. This makes REPL a Small Cap stock.
What is the outstanding short interest for REPLIMUNE GROUP INC?
The outstanding short interest for REPLIMUNE GROUP INC (REPL) is 19.39% of its float.
REPL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to REPL. When comparing the yearly performance of all stocks, REPL is one of the better performing stocks in the market, outperforming 93.04% of all stocks.
REPL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to REPL. REPL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
REPL Financial Highlights
Over the last trailing twelve months REPL reported a non-GAAP Earnings per Share(EPS) of -3.46. The EPS decreased by -13.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.58% | ||
| ROE | -117.69% | ||
| Debt/Equity | 0.26 |
REPL Forecast & Estimates
14 analysts have analysed REPL and the average price target is 12.82 USD. This implies a price increase of 28.67% is expected in the next year compared to the current price of 9.9654.
For the next year, analysts expect an EPS growth of -19.28% and a revenue growth -100% for REPL